Dr. Adriana Larregina is an Associate Professor of Dermatology and Immunology in the University of Pittsburgh School of Medicine. She is also the Director of Cutaneous Laboratories and Education in the Department of Dermatology. In addition, she is a faculty member of the Graduate Program in Immunology, University of Pittsburgh School of Medicine.
Dr. Larregina earned her medical degree at National University of La Plata in Buenos Aires, Argentina, where she graduated magna cum laude. After an internship in general medicine at the Hospital “San Roque” La Plata, Buenos Aires, Dr. Larregina completed a residency in pathology at the University of Buenos Aires, where she was chief resident during her final year. She then did a fellowship in pediatric pathology, Children’s Hospital of La Plata. She earned her PhD in Immunology at the University of Buenos Aires School of Medicine, where she finished summa cum laude, and did her postdoctoral research in gene therapy with the Molecular Medicine Unit, Department of Medicine at Victoria University of Manchester in the United Kingdom. Upon completion, she came to the University of Pittsburgh.
Dr. Larregina’s current research interests include:
- Use of adjuvants for skin genetic immunizations: Transfection and activation of human and mouse skin dendritic cells. The purpose of the research project is to deliver a method of genetic vaccines for human tumors and infectious diseases.
- Study of the relevance of pro-inflammatory neuropeptides released in the skin (i.e.: substance P (SP)) to promote immunestimulatory function of mouse and human dendritic cells generated ex vivo. The project is analyzing the possibility of inducing potent immune responses to foreign Ag by stimulation of ex vivo generated DCs with SP, Hemokinin-1, and SP analogs. Also this project evaluates the relevance and the mechanism involved in the immune-stimulatory functions of SP to promote skin inflammation and autoimmunity.
- Use of antagonists of the NK1R to block pro-inflammatory signaling in skin inflammatory and autoimmune diseases. The project objectives include the use of synthetic antagonists of the NK1R to abrogate skin inflammation and autoimmunity.
- Use of NK1R antagonists for allograft acceptance and survival. This project will analyze the role of blocking inflammatory signaling via the NK1R for engraftment and survival of allogeneic transplants.
- Study of the relevance of different skin resident Dendritic cells in the context of the immunobiology of the skin. The project objectives include to determine the immunological function of CD14+ and CD14- human skin DCs and to characterize the population of mouse skin CD14+ and CD14- DCs.
- To analyze the ability of hematopoietic precursors resident in the skin to generate in situ DCs. Dr. Larregina’s laboratory has described that human skin contains hematopoietic progenitors. The team will analyze the ability and the mechanisms involved in the local generation of DCs and other leukocytes in the skin.
Dr. Larrengina is an associate editor of the Journal of Clinical and Experimental Dermatology. Dr. Larregina is also a member of the Society for Investigative Dermatology, the American Association of Immunologists, the International Endotoxin & Innate Immunity Society, and the International Society of Exosomes and Microvesicles.
View Dr. Larrengina’s publications here.
Dr. Adriana Larregina
Phone: (412) 383-9842